<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127642">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01761175</url>
  </required_header>
  <id_info>
    <org_study_id>PEJ-666</org_study_id>
    <nct_id>NCT01761175</nct_id>
  </id_info>
  <brief_title>Comparison of Ultrasound-Guided Infraclavicular Block and Ultrasound-Guided Axillary Block</brief_title>
  <official_title>Comparison of Ultrasound-Guided Single Injection Infraclavicular Block or Ultrasound-Guided Double Injection Axillary Block : A Prospective Randomized Blinded Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariane Boivin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Québec, CHU de Québec</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate of complete sensory block at 30 minutes
      following ultrasound-guided single injection infraclavicular block and ultrasound-guided
      double injection axillary block. The investigators research hypothesis is that both blocks
      will show comparable rates of complete sensory block at 30 minutes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with complete sensory block</measure>
    <time_frame>30 minutes after block completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete sensory block is defined by anesthesia to cold sensation in the ulnar, radial, median and musculocutaneous nerves territories.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with complete motor blocks</measure>
    <time_frame>30 minutes after block completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete motor block is defined by paralysis in the ulnar, radial, median and musculocutaneous nerves territories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete sensory and motor blocks.</measure>
    <time_frame>0, 5, 10, 15, 20, 25 and 30 minutes after block completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensory and motor blocks are evaluated in the median, ulnar, radial and musculocutaneous nerves territories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related pain on a visual analog pain scale</measure>
    <time_frame>During the nerve block procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events related to nerve block</measure>
    <time_frame>24 hours and 1 month after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical block success rate</measure>
    <time_frame>End of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Surgical block success is defined by a nerve block allowing surgery without a rescue block, an infiltration of local anesthetics by the surgeon, administration of analgesics for pain in the surgical field or a general anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance time of the nerve block</measure>
    <time_frame>During the performance of the block</time_frame>
    <safety_issue>No</safety_issue>
    <description>Performance time is defined as the sum of imaging time (defined as the time elapsed from the moment the Doppler probe is in contact with the patient to the insertion of the Tuohy needle) and needling time (from the insertion of the needle to its complete removal).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ultrasound-guided infraclavicular block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound-guided single injection infraclavicular block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound-guided axillary block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound-guided double injection axillary block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided infraclavicular block</intervention_name>
    <description>Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.</description>
    <arm_group_label>Ultrasound-guided infraclavicular block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided axillary block</intervention_name>
    <description>Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.</description>
    <arm_group_label>Ultrasound-guided axillary block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  American Society of Anesthesiologists Class 1 to 3

          -  Undergoing a surgery at the elbow, forearm, wrist or hand under regional anesthesia

        Exclusion Criteria:

          -  Age less than 18 years

          -  Body mass index more than 40 kg/m2

          -  Weight less than 45 kg

          -  Patient refusal

          -  Contraindication to regional anesthesia (coagulopathy, local infection at the
             puncture site, systemic infection)

          -  Previous neurological deficit in the operated arm

          -  Severe renal or hepatic failure

          -  Prior surgery in the axillary or infraclavicular area

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariane Boivin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Josée Nadeau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Dion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Lévesque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre C. Nicole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexis F. Turgeon, MD, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de l'Enfant-Jésus</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Saint-Sacrement</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 9, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Québec, CHU de Québec</investigator_affiliation>
    <investigator_full_name>Ariane Boivin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
